Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess Safety and Efficacy of ANG003

NCT06052293
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
ANG003
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

NCT02025621
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions
Levosimendan, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

NCT00975819
View directory record Official record
Conditions
Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation, Microcystic Lymphatic Malformation, Mucocutaneous Lymphangiomatosis and Thrombocytopenia, Capillary Lymphatic Arterial Venous Malformations, PTEN Overgrowth Syndrome With Vascular Anomaly, Lymphangiectasia Syndromes
Interventions
sirolimus
Drug
Lead sponsor
Denise Martin Adams
Other
Eligibility
Up to 31 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 31, 2026, 11:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 11:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
39
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 31, 2026, 11:24 AM EDT
Completed No phase listed Observational

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

NCT01474811
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
13,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
55
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Not applicable Interventional

A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI

NCT01149044
View directory record Official record
Conditions
Acute Coronary Syndrome, ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Percutaneous Coronary Intervention with or without manual aspiration thrombectomy
Procedure
Lead sponsor
Population Health Research Institute
Other
Eligibility
19 Years and older
Enrollment
10,732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
8
States / cities
Bakersfield, California • Atlanta, Georgia • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498
View directory record Official record
Conditions
Myelofibrosis
Interventions
Simtuzumab, Ruxolitinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Stanford, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 31, 2026, 11:24 AM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763
View directory record Official record
Conditions
Hemophilia A
Interventions
Efanesoctocog Alfa BIVV001
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

NCT00870584
View directory record Official record
Conditions
Persistent Allergic Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Jasper, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 31, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Tadalafil for Duchenne Muscular Dystrophy

NCT01865084
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 14 Years · Male only
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 3 Interventional Results available

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

NCT05323734
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 31, 2026, 11:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.

NCT01850134
View directory record Official record
Conditions
Diabetes
Interventions
Experimental Study Product, Control Study Product
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Addison, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 31, 2026, 11:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 11:24 AM EDT
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 31, 2026, 11:24 AM EDT
Terminated Phase 2 Interventional

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

NCT00662116
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
alagebrium, placebo
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 31, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional Results available

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319
View directory record Official record
Conditions
Steroid-Refractory Acute Graft Versus Host Disease
Interventions
T-Guard
Drug
Lead sponsor
Xenikos
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
24
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

NCT02100436
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Not applicable Interventional

Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee

NCT01754298
View directory record Official record
Conditions
Juvenile Osteochondritis Dissecans
Interventions
Retro-articular drilling, Trans-articular drilling
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Centennial, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 31, 2026, 11:24 AM EDT
Enrolling by invitation No phase listed Observational

A Clinical Registry of Orthobiologics Procedures

NCT03011398
View directory record Official record
Conditions
Orthopedic Disorder
Interventions
Orthobiologic Procedures
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Oceanside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 31, 2026, 11:24 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 31, 2026, 11:24 AM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 31, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Early Administration of Steroids in the Ambulance Setting

NCT03962894
View directory record Official record
Conditions
Asthma in Children
Interventions
Prednisolone
Drug
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 18 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
DeFuniak Springs, Florida • Fort Myers, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 31, 2026, 11:24 AM EDT